{"id":25900,"date":"2023-04-28T12:55:33","date_gmt":"2023-04-28T10:55:33","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/contacts\/adverse-event-reporting\/"},"modified":"2023-05-22T12:20:25","modified_gmt":"2023-05-22T12:20:25","slug":"adverse-event-reporting","status":"publish","type":"page","link":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/contacts\/adverse-event-reporting\/","title":{"rendered":"Signalement d’\u00e9v\u00e8nements ind\u00e9sirables"},"content":{"rendered":"\n
<\/p>\n \n
\n adverse.events@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.algeria@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.australia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.germany@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.belgium@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.brasil@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.canada@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.china@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.hongkong@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.colombia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.czech@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.france@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.germany@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.greece@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.hungary@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.uk-ie@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.italy@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pv.japan@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.kazakhstan@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.korea@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.baltic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.baltic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.belgium@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.mexico@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.netherlands@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.poland@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.portugal@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.romania@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.russia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.sg@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.slovakia@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.spain@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.nordic@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.germany@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.taiwan@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.tunisie@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.ukraine@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n \n pharmacovigilance.ksa@ipsen.com<\/a>\n <\/p>\n \n <\/p>\n <\/div>\n <\/div>\n <\/div>\n Alg\u00e9rie<\/h4>\n \n\n
Australie<\/h4>\n \n\n
Autriche<\/h4>\n \n\n
Belgique<\/h4>\n \n\n
Br\u00e9sil<\/h4>\n \n\n
Canada<\/h4>\n \n\n
Chine<\/h4>\n \n\n
Hong Kong – PRC<\/h4>\n \n\n
Colombie<\/h4>\n \n\n
R\u00e9publique Tch\u00e8que<\/h4>\n \n\n
Danemark<\/h4>\n \n\n
Finlande<\/h4>\n \n\n
France<\/h4>\n \n\n
Allemagne<\/h4>\n \n\n
Gr\u00e8ce<\/h4>\n \n\n
Hongrie<\/h4>\n \n\n
Irlande<\/h4>\n \n\n
Italie<\/h4>\n \n\n
Japon<\/h4>\n \n\n
Kazakhstan<\/h4>\n \n\n
Cor\u00e9e du Sud<\/h4>\n \n\n
Lettonie<\/h4>\n \n\n
Lituanie<\/h4>\n \n\n
Luxembourg<\/h4>\n \n\n
Mexique<\/h4>\n \n\n
Pays-Bas<\/h4>\n \n\n
Norv\u00e8ge<\/h4>\n \n\n
Pologne<\/h4>\n \n\n
Portugal<\/h4>\n \n\n
Roumanie<\/h4>\n \n\n
Russie<\/h4>\n \n\n
Singapour<\/h4>\n \n\n
Slovaquie<\/h4>\n \n\n
Espagne<\/h4>\n \n\n
Su\u00e8de<\/h4>\n \n\n
Suisse<\/h4>\n \n\n
Taiwan<\/h4>\n \n\n
Tunisie<\/h4>\n \n\n
Ukraine<\/h4>\n \n\n
Emirats Arabes Unis<\/h4>\n \n\n